RxDoctor Payments DataLook up a doctor →

Benjamin Roberts, PA

Physician Assistant · Spanish Fork, UTNPI 1922653039

Payments from drug & device makers

$7,510in general payments, 2019–2025

Across 422 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boehringer Ingelheim$431
  • AstraZeneca$424
  • Lilly USA, LLC$423
  • Supernus Pharmaceuticals, Inc.$409
  • Novo Nordisk$316
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,46399%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,510 in reported general payments places this provider in the 95th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$34,641
Medicare patients
67
Services billed
629

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol55$58,153
EliquisApixaban53$49,746
OzempicSemaglutide33$48,403
MounjaroTirzepatide27$40,205
JardianceEmpagliflozin40$40,016
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$35,862
VraylarCariprazine Hcl19$27,584
JanuviaSitagliptin Phosphate15$23,653
Spiriva RespimatTiotropium Bromide29$17,307
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$14,492
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$9,718
KerendiaFinerenone13$8,387
Humalog Kwikpen U-100Insulin Lispro18$8,191
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$7,367
Albuterol Sulfate HfaAlbuterol Sulfate179$5,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$424$94,01599 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$431$71,81599 claims
PfizerEliquis$157$49,74653 claims
Novo NordiskOzempic$316$48,40333 claims
Lilly USA, LLCMounjaro$423$40,20527 claims
AbbVieVraylar, Synthroid$2,253$28,78932 claims
MerckJanuvia$120$23,65315 claims
BayerKerendia$206$8,38713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Spanish Fork

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →